Vimarsana
Biggest News Aggregation in the World

Page 2 - John Bluth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Bluth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Bluth Today - Breaking & Trending Today

BioCryst to Present at Upcoming Investor Conferences - Vimarsana News

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx Conference

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with ... - Vimarsana News

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with ...

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) leading to a

BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript - Vimarsana News

BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2023.

Source: fool.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Call Transcript - Vimarsana News

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Call Transcript

Operator: Good morning and welcome to the BioCryst Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2023 -- BioCryst Pharmaceuticals, Inc. today announced that the compensation committee of BioCryst’s board of directors granted 23 newly-hired employees...